Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
IrelandIPO:
16 November 2023Website:
http://www.muraloncology.comNext earnings report:
29 November 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Fri, 01 Nov 2024 13:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
MURA Latest News
WALTHAM, Mass and DUBLIN, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced the appointment of Sachiyo Minegishi to its board of directors, effective September 20. Ms. Minegishi will serve as Chair of the Audit Committee and will also be joining the company's Nominating and Corporate Governance Committee.
Company remains well positioned to capitalize on the role of cytokines with near- and long-term potential value creation milestones, reiterates guidance on projected cash runway into Q4 2025
WALTHAM, Mass and DUBLIN, July 31, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced the appointment of George Golumbeski, Ph.D., to its board of directors effective July 30.
WALTHAM, Mass. and DUBLIN, June 05, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that Caroline Loew, Ph.D., CEO, will present at the East Coast IDEAS Investor Conference on June 13 at 9:15 a.m. EST. A webcast will be available at www.threepartadvisors.com/east-coast and ir.muraloncology.com.
Mural Oncology trades at approximately $5, a material discount to cash holdings of over $16/share, as reported in November 2023. The pipeline of 3 major candidates of cytokine cancer therapies at different stages in clinical trials may offer material value if things go well. As a spin-off since November 2023, Mural may receive investor attention in 2024 as it starts to attend industry conferences and releases financial reports.
What type of business is Mural Oncology?
Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.
What sector is Mural Oncology in?
Mural Oncology is in the Healthcare sector
What industry is Mural Oncology in?
Mural Oncology is in the Biotechnology industry
What country is Mural Oncology from?
Mural Oncology is headquartered in Ireland
When did Mural Oncology go public?
Mural Oncology initial public offering (IPO) was on 16 November 2023
What is Mural Oncology website?
https://www.muraloncology.com
Is Mural Oncology in the S&P 500?
No, Mural Oncology is not included in the S&P 500 index
Is Mural Oncology in the NASDAQ 100?
No, Mural Oncology is not included in the NASDAQ 100 index
Is Mural Oncology in the Dow Jones?
No, Mural Oncology is not included in the Dow Jones index
When was Mural Oncology the previous earnings report?
No data
When does Mural Oncology earnings report?
The next expected earnings date for Mural Oncology is 29 November 2024